Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:32 PM ET 10-Q
Financial Results LENSAR, Inc. LNSR

LENSAR Q3 2026 Results: Net Loss of $4.72M, Loss Widens

LENSAR, Inc. is focused on the commercialization of its ALLY Robotic Cataract Laser System while navigating the aftermath of a terminated Merger Agreement. The company continues to report operating losses and emphasizes risks related to macroeconomic conditions, regulatory clearances, and patient willingness to pay for advanced cataract procedures.

Key figure
Net loss $4.72M
4:32 PM ET 10-Q
Financial Results Stran & Company, Inc. SWAG ▶ Call

Stran & Company Q3 2026 Results: Turns Profitable, Net Income $35K

Stran & Company, Inc. reported a net income of $1.09 million for the nine months ended September 30, 2026, compared to a net loss of $0.99 million in the prior year period. Total sales increased to $92.7 million from $87.3 million, while the company maintained a strong cash position of $7.38 million as of the end of the third quarter.

Key figure
Net income $35K
4:32 PM ET 10-Q
Financial Results Harvard Bioscience Inc HBIO

Harvard Bioscience Q3 2026 Results: Net Loss of $2.62M, Loss Widens

Harvard Bioscience reported revenues of $22.2 million for Q3 2026, a slight increase from $20.6 million in the prior year, though the company recorded a net loss of $2.6 million. For the nine months ended September 30, 2026, the net loss was $9.0 million compared to a $53.9 million loss in 2025, which had been driven by a significant $48.0 million goodwill impairment charge.

Key figure
Net loss $2.62M
4:32 PM ET 10-Q
Financial Results Biomea Fusion, Inc. BMEA

Biomea Fusion Q3 2026 Results: Net Loss of $6.18M, Loss Narrows

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for diabetes and obesity. The filing indicates substantial doubt about the company's ability to continue as a going concern, highlighting a critical need for additional capital to fund ongoing research and development of its lead candidates, icovamenib and BMF-650.

Key figure
Net loss $6.18M
4:32 PM ET 10-Q
Financial Results Humacyte, Inc. HUMA

Humacyte Q3 2026 Results: Net Loss of $15.5M, Loss Narrows

Humacyte, Inc. reported a significant increase in cash and cash equivalents to $64.5 million as of September 30, 2026, following the commercialization of Symvess. The company recorded a litigation settlement liability of $9.75 million and an accumulated deficit of $796.8 million, while common stock outstanding grew to over 277 million shares.

Key figure
Net loss $15.5M
4:32 PM ET 8-K
Financial Results Meridian Holdings Inc. MRDN

Meridian Holdings Financial Results

Meridian Holdings reported Q3 2026 revenue of $46.0 million, a 3% year-over-year decrease, and a net loss of $13.3 million. The loss was primarily driven by $11.5 million in non-cash impairment charges, including a full write-off of its Brazilian gaming license following regulatory changes. Despite the quarterly loss, nine-month revenue rose 10% to $146.3 million and the company reduced total debt by 47% to $24.1 million.

Term
Q3 2026

“This was a challenging quarter, impacted by customer-favorable sports results, regulatory developments in Brazil and higher operating costs. Brazil suspended fixed-odds betting, including online casinos, by all operators. Our core business remains healthy and outside one-off adjustments continues to generate cash to drive its own growth.”

Zoran Milosevic, Chief Executive Officer of Meridian Holdings

“In the fourth quarter, historically our strongest, we expect higher betting volume and continued momentum in online casino. We remain focused on improving margins and driving operational efficiency through more targeted marketing and promotional costs, continued optimization of our retail footprint and expected growth in higher-margin online casino, with a goal of returning to the profitability we demonstrated in the first half of 2026.”

Zoran Milosevic, Chief Executive Officer of Meridian Holdings
4:31 PM ET 10-Q
Financial Results Maxcyte, Inc. MXCT

Maxcyte Q3 2026 Results: Net Loss of $4.76M, Loss Narrows

MaxCyte reported revenue of $10.2 million for the third quarter of 2026, a significant increase from $6.8 million in the prior year period. The company successfully reduced its quarterly net loss to $4.8 million from $12.4 million year-over-year, driven by higher gross profits and a substantial reduction in operating expenses across R&D and sales and marketing.

Key figure
Net loss $4.76M
4:31 PM ET 10-Q
Financial Results Capstone Companies, Inc. CAPC

Capstone Companies Q3 2026 Results: Net Loss of $57K, Loss Narrows

Capstone Companies, Inc. reported zero revenue for the nine months ended September 30, 2026, as it continues to search for a new business line. The company incurred a net loss of $234,143 and faces substantial doubt about its ability to continue as a going concern due to negative working capital and maturing debt obligations.

Key figure
Net loss $57K
4:31 PM ET 10-Q
Financial Results Precipio, Inc. PRPO

Precipio Q3 2026 Results: Net Loss of $8K, Loss Narrows

Precipio, Inc. reported net sales of $21.1 million for the nine months ended September 30, 2026, a significant increase from $17.4 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $1.67 million for the first nine months of 2026, compared to a net loss of $0.89 million in 2025, primarily driven by higher operating expenses.

Key figure
Net loss $8K
4:31 PM ET 10-Q
Financial Results Acme United Corp ACU

Acme United Q3 2026 Results: Net Income $3.44M, Up 80.5% YoY

Acme United Corp reported net sales of $173.0 million for the nine months ended September 30, 2026, a 16% increase over the prior year, driven in part by the acquisition of My Medic assets. Net income for the same period rose to $9.5 million, while the company significantly increased its long-term debt to $28.1 million to fund investing activities.

Key figure
Net income $3.44M · +80.5% YoY
4:31 PM ET 10-Q
Financial Results Beyond Meat, Inc. BYND

Beyond Meat Q3 2026 Results: Net Loss of $82.8M, Loss Narrows

Beyond Meat, Inc. is undergoing a strategic repositioning to 'Beyond The Plant Protein Company,' expanding into adjacent categories like powders, bars, and beverages. The company recently completed a 1-for-30 reverse stock split and an exchange offer for its convertible senior notes to address significant debt and liquidity concerns.

Key figure
Net loss $82.8M
4:31 PM ET 10-Q
Financial Results Tofutti Brands Inc TOFB

Tofutti Brands Q3 2026 Results: Net Loss of $12K, Loss Narrows

Tofutti Brands Inc. reported a net loss of $386,000 for the thirty-nine weeks ended September 26, 2026, as net sales declined to $4.58 million from $5.53 million in the prior year period. The company issued a going concern warning, noting that existing cash and anticipated flows are insufficient to fund operations for the next twelve months.

Key figure
Net loss $12K
4:31 PM ET 8-K
Financial Results Intelligent Bio Solutions Inc. INBS

Intelligent Bio Solutions Financial Results

Intelligent Bio Solutions reported record fiscal first quarter 2027 revenue of $1.39 million, a 25% increase year-over-year, driven by higher-margin cartridge sales. The company also achieved a significant regulatory milestone by submitting its FDA 510(k) premarket notification for its fingerprinting drug screening system, targeting the U.S. market.

Term
Q1 2027

“Fiscal first quarter revenue was the highest quarterly revenue in our Company’s history. Each reader draws on a recurring supply of higher-margin cartridges, which is driving most of our revenue growth. Our business continues to scale with improving unit economics, including expanding gross profit margins driven by manufacturing efficiencies and a higher share of revenue from higher-margin cartridge consumables.”

Harry Simeonidis, President and CEO

“In September, we submitted our 510(k) premarket notification to the FDA for the Intelligent Fingerprinting Drug Screening System, the culmination of the clinical program we executed throughout 2026 and a key step toward our planned entry into the multi-billion-dollar U.S. drug screening market. Going forward, we will continue to invest in the clinical and regulatory work behind our 510(k) submission while maintaining discipline across the rest of the business.”

Harry Simeonidis, President and CEO
4:31 PM ET 8-K
Financial Results Energy Vault Holdings, Inc. NRGV

Energy Vault Holdings Financial Results

Energy Vault reported Q3 2026 revenue of $13.1 million and a significant increase in contract backlog to $2.3 billion, up 147% year-over-year. The company affirmed its full-year 2026 revenue guidance of $290-$310 million and provided preliminary 2027 revenue guidance of $600-$700 million as it transitions toward a Build, Own & Operate strategy.

Term
Q3 2026

“During the third quarter, we continued advancing our integrated Build, Own & Operate strategy, expanding our global development pipeline and strengthening our cash and overall financial position. Our backlog reached $2.3 billion as of November 10th, third quarter total cash increased almost 3x year-over-year, and we achieved important financing, acquisition and development milestones that support the long-term growth of our owned infrastructure platform.”

Robert Piconi, Chairman and Chief Executive Officer
4:31 PM ET 10-Q
Financial Results Seer, Inc. SEER

Seer Q3 2026 Results: Net Loss of $13.7M, Loss Narrows

For the nine months ended September 30, 2026, Seer, Inc. reported total revenue of $9.9 million, a decrease from $12.4 million in the prior year period. The company reduced its net loss to $47.5 million compared to $57.6 million in 2025, primarily driven by a significant reduction in research and development and SG&A operating expenses.

Key figure
Net loss $13.7M
4:31 PM ET 10-Q
Financial Results Strategic Storage Trust VI, Inc. SGST

Strategic Storage Trust VI Q3 2026 Results: Net Loss of $7.4M, Loss Narrows

Strategic Storage Trust VI, Inc. reported a net loss of approximately $25.5 million for the nine months ended September 30, 2026, compared to a loss of $18.5 million in the prior year period. Total revenues increased slightly to $23.9 million, but the company faced higher operating expenses and significant foreign currency adjustments that impacted the bottom line.

Key figure
Net loss $7.4M
4:29 PM ET 8-K
Financial Results Amprius Technologies, Inc. AMPX

Amprius Technologies Financial Results

Amprius Technologies reported record Q3 2026 revenue of $39.1 million, an 83% year-over-year increase driven by strong demand in drone, aviation, and defense markets. The company improved its GAAP net loss to $3.5 million and raised its full-year 2026 revenue outlook to $145 million.

Term
Q3 2026

“Our third quarter results demonstrate the strength of our company’s technology leadership and our ability to convert growing customer demand into meaningful financial performance. We delivered record revenue, as we continued to deepen our relationships with customers across the drone, aviation, defense, and advanced mobility markets.”

Tom Stepien, CEO
4:29 PM ET 8-K
Financial Results Quicklogic Corp QUIK

Quicklogic Financial Results

QuickLogic reported fiscal third quarter 2026 revenue of $5.1 million, a 153% increase year-over-year, driven by strong growth in new product revenue. The company reported a GAAP net loss of $2.2 million ($0.12 per share) and highlighted a recent six-figure eFPGA design win in the automotive industrial sector.

Term
Q3 2026

“Our recent automotive and industrial design win is a strong validation of our eFPGA technology. Combined with our latest eFPGA Hard IP advancements and continued progress on the U.S. strategic radiation-hardened FPGA program, we are building momentum across key areas of our business and anticipate a strong finish to the year.”

Brian Faith, CEO of QuickLogic
4:28 PM ET 8-K
Financial Results Inhibikase Therapeutics, Inc. IKT

Inhibikase Therapeutics Financial Results

Inhibikase Therapeutics reported financial results for the third quarter of 2026, highlighting the expansion of its Phase 3 IMPROVE-PAH study for IKT-001 with 28 country regulatory approvals and 79 clinical sites activated. The company noted it is well-capitalized following a $50 million equity sale to RA Capital in July 2026, which will support the advancement of its PAH clinical program.

Term
Q3 2026

“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries.”

Mark Iwicki, Chief Executive Officer of Inhibikase

“Supported by the $50 million proceeds from the sale of shares to RA Capital in July, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”

Mark Iwicki, Chief Executive Officer of Inhibikase
4:28 PM ET 10-Q
Financial Results Finwise Bancorp FINW

Finwise Bancorp Q3 2026 Results: Net Income $10M, Up 105.4% YoY

FinWise Bancorp reported total assets of $83.8 million in interest-bearing deposits as of September 30, 2026, a decrease from $151.3 million at year-end 2025. The company is focusing on its Banking-as-a-Service (BaaS) expansion and the integration of its recent acquisition of Tallied Technologies, Inc. to optimize its technology platform.

Key figure
Net income $10M · +105.4% YoY
4:28 PM ET 8-K
Financial Results Biomea Fusion, Inc. BMEA

Biomea Fusion Financial Results

Biomea Fusion reported financial results for the third quarter of 2026, highlighting the completion of enrollment in its Phase II COVALENT-211 trial for icovamenib in type 2 diabetes. The company also reported positive Phase I results for its oral GLP-1 RA candidate, BMF-650, and projected its cash runway into the second quarter of 2027.

Term
Q3 2026

“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance enrollment in our Phase II COVALENT-212 clinical trial, bringing us closer to important Phase II data readouts for icovamenib in two distinct diabetes populations that we estimate represent over 30% of treated patients with diabetes in the U.S.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer

“We also reported first-in-human results for BMF-650, providing initial clinical support for our design hypothesis, in that BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer
4:26 PM ET 10-Q
Financial Results NextCure, Inc. NXTC

NextCure Q3 2026 Results: Net Loss of $6.85M, Loss Narrows

NextCure reported a net loss of $31.5 million for the nine months ended September 30, 2026, an improvement from the $46.4 million loss in the prior year period. The company's cash position decreased significantly to $8.7 million as it underwent restructuring and asset impairment charges totaling $3.0 million.

Key figure
Net loss $6.85M
4:26 PM ET 10-K
Financial Results E-Smart Corp. ESMR

E-Smart FY 2026 Results: Net Loss of $128K, Loss Widens

E-Smart Corp. reported a net loss of $127,976 for the fiscal year ended August 31, 2026, compared to a loss of $68,034 in 2025, driven by a significant increase in general and administrative expenses. The company's independent auditor issued a going concern warning due to an accumulated deficit of $238,225 and recurring negative cash flows from operations.

Key figure
Net loss $128K
4:26 PM ET 8-K
Financial Results Big Sky Industrial Inc. BSIN

Big Sky Industrial Financial Results

Big Sky Industrial reported Q3 2026 financial results and provided a construction update on its flagship Big Sky Carbon Hub project in Montana. The company confirmed that Phase 1 fabrication is underway with first production targeted for spring 2027, supported by a five-year, 100% take-or-pay helium offtake agreement.

“The third quarter was about execution, and we are pleased with where the project stands. Our in-field gathering and injection lines are complete, and our long-lead equipment has been procured, including the natural gas-fired generators that will power the plant. Plant fabrication is underway, on-site civil work begins in the coming weeks, and construction remains on schedule.”

Ryan Smith, President and Chief Executive Officer

“We are targeting first production in spring 2027, a window that leaves sensible room for commissioning and the Montana winter. From day one, our helium is sold under a five-year, 100% take-or-pay contract. In October, the Department of Energy designated helium a critical material, which underscores the value of the domestic supply we are building in Montana.”

Ryan Smith, President and Chief Executive Officer
4:25 PM ET 8-K
Financial Results StubHub Holdings, Inc. STUB

StubHub Holdings Financial Results

StubHub reported Q3 2026 financial results with revenue increasing 7% year-over-year to $502 million and Gross Merchandise Sales (GMS) reaching $2.6 billion. The company also announced a leadership transition, appointing Michael Noonan as CFO to succeed Connie James effective January 4, 2027. Based on strong performance, StubHub raised its full-year 2026 GMS outlook to a range of $10.175 billion to $10.375 billion.

Term
Q3 2026

“Consumers continue to prioritize live events and value the trusted experience that StubHub provides as the global market leader. We are increasing our full-year GMS outlook to reflect our positive third quarter results and anticipated performance for the remainder of the year. Moving forward, we remain committed to advancing StubHub’s strategic priorities that expand access and choice for fans.”

Eric Baker, Founder, Chairman and Chief Executive Officer
4:24 PM ET 10-Q
Financial Results Lightpath Technologies Inc LPTH

Lightpath Technologies Q1 2026 Results: Net Loss of $1.7M, Loss Narrows

LightPath Technologies reported revenue of $20.8 million for the quarter ended September 30, 2026, a 38% increase compared to the prior year. Despite the revenue growth, the company recorded a net loss of $1.7 million, driven by significantly higher operating expenses in selling, general, and administrative costs and new product development.

Key figure
Net loss $1.7M
4:24 PM ET 8-K
Financial Results Sonos Inc SONO

Sonos Financial Results

Sonos reported fiscal year 2026 revenue growth of 7% to $1.55 billion and a 39% increase in Adjusted EBITDA to $184 million. Alongside the results, the company announced that its Board of Directors authorized a new $150 million common stock repurchase program following the completion of its previous buyback program.

“We said Fiscal 2026 would be the year Sonos returned to growth, and we delivered. We grew in every region, delivered meaningfully higher profitability, and brought five new products to market. Underneath it all, the system strategy is working - every product improves those our customers already own, and with Sonos 27, that will keep getting stronger every year.”

Tom Conrad, Chief Executive Officer of Sonos

“Fiscal 2026 demonstrated how much the earning power of Sonos has structurally improved. We grew revenue 7%, reduced Non-GAAP operating expenses 3% and grew Adjusted EBITDA 39% to $184 million, all while absorbing $56 million of higher memory costs. That’s the foundation we’re building on, and we’re actively managing the levers available to us to optimize our financial performance.”

Saori Casey, Chief Financial Officer of Sonos
4:24 PM ET 8-K
Financial Results Context Therapeutics Inc. CNTX

Context Therapeutics Financial Results

Context Therapeutics reported Q3 2026 financial results and provided a clinical update on its CTIM-76 program, which showed a 22% confirmed ORR and 5.6 months median PFS in platinum-resistant ovarian cancer. The company ended the quarter with $34.4 million in cash, providing a runway into Q4 2027.

Term
Q3 2026

“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy. Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness, providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.”

Martin Lehr, Chief Executive Officer
4:23 PM ET 8-K
Financial Results Palisade Bio, Inc. PALI

Palisade Bio Financial Results

Palisade Bio reported third quarter 2026 financial results and provided a clinical update on its PALI-2108 programs, including the initiation of the Phase 2b ASCENTRA-UC trial. The company ended the quarter with $113.6 million in cash and expects topline results from the UC trial in Q4 2027.

“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”

JD Finley, Chief Executive Officer of Palisade Bio

“In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”

JD Finley, Chief Executive Officer of Palisade Bio
4:22 PM ET 8-K
Financial Results Seer, Inc. SEER

Seer Financial Results

Seer, Inc. reported third quarter 2026 revenue of $4.0 million, a sequential increase from $3.1 million in Q2 2026, driven by consumable purchases from established customers and new pharmaceutical platform adoptions. The company ended the quarter with $198.1 million in cash and updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.

Term
Q3 2026

“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform.”

Omid Farokhzad, Chair and Chief Executive Officer

“Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use. With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”

Omid Farokhzad, Chair and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.